Atea Net Income From Continuing Ops from 2010 to 2024

AVIR Stock  USD 3.46  0.16  4.85%   
Atea Pharmaceuticals Net Loss yearly trend continues to be relatively stable with very little volatility. Net Loss is likely to grow to about -129.2 M this year. During the period from 2010 to 2024, Atea Pharmaceuticals Net Loss destribution of quarterly values had range of 257.1 M from its regression line and mean deviation of  41,032,688. View All Fundamentals
 
Net Loss  
First Reported
2019-09-30
Previous Quarter
-63.2 M
Current Value
-40.5 M
Quarterly Volatility
38 M
 
Covid
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 30.7 M, Interest Income of 30.7 M or Depreciation And Amortization of 436.8 K, as well as many indicators such as Price To Sales Ratio of 2.3, Dividend Yield of 0.0 or PTB Ratio of 0.48. Atea financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Atea Pharmaceuticals Correlation against competitors.
To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

Latest Atea Pharmaceuticals' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Atea Pharmaceuticals over the last few years. It is Atea Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atea Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Atea Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(24,426,013)
Geometric Mean19,038,410
Coefficient Of Variation(257.52)
Mean Deviation41,032,688
Median(9,064,000)
Standard Deviation62,902,720
Sample Variance3956.8T
Range257.1M
R-Value(0.41)
Mean Square Error3530.5T
R-Squared0.17
Significance0.12
Slope(5,824,319)
Total Sum of Squares55394.5T

Atea Net Income From Continuing Ops History

2024-129.2 M
2023-136 M
2022-115.9 M
2021121.2 M
2020-10.9 M
2019-14 M

About Atea Pharmaceuticals Financial Statements

Atea Pharmaceuticals shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Atea Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Atea Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-136 M-129.2 M

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Atea Stock

  0.64VALN Valneva SE ADRPairCorr
  0.75FDMT 4D Molecular TherapeuticsPairCorr
  0.77JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.67LLY Eli Lilly Sell-off TrendPairCorr

Moving against Atea Stock

  0.7BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.55GILD Gilead SciencesPairCorr
  0.53NAMS NewAmsterdam PharmaPairCorr
  0.4LPCN LipocinePairCorr
  0.38MNOV MediciNovaPairCorr
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.